THANK YOU FOR SUBSCRIBING
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
This system also enables cardiologists to deliver custom-tailored therapy as it enables them to place the device in the most favorable pacing location in the LV as per the patient’s medical requirement, rendering the best possible outcomes. Besides, it works seamlessly with the previously implanted pacemaker or any co-implant device that paces the right ventricle. WiSE paces the LV at the same time as the right side to restore the heart’s synchrony. The WiSE CRT System is already approved in Europe, while EBR Systems is performing an IDE study in the US.![]()
We have developed the first wireless endocardial pacing system for heart failure that can be implanted in any favorable location inside the left ventricle to offer tailored pacing therapy to patients
Share this Article:
Tweet
|
Company
EBR Systems
Headquarters
Sunnyvale, CA
Management
Andrew Shute, Senior Vice President, Global Field Operations
Description
Delivers superior treatment for patients suffering from cardiac rhythm diseases by developing safe, clinically superior, cost-effective and reliable therapies using wireless cardiac stimulation. The company is on a mission to eliminate pacing leads and deliver top-of-the-line, reliable, and patient-specific treatment for cardiac rhythm diseases that would significantly help patients unable to benefit from the traditional CRT. EBR Systems’ WiSE CRT system is a leadless, customizable, and endocardial (inside the LV) therapy
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info